Gene: CGNL1

84952
JACOP|PCING
cingulin like 1
protein-coding
15q21.3
Ensembl:ENSG00000128849 MIM:607856 Vega:OTTHUMG00000166485 UniprotKB:Q0VF96
NG_030584.1
SNP Mapped
2   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
4.024e-3 (AD)  9.639e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs8034838chr15:57441989 (GRCh38.p7)G>Calcohol dependenceSNV(Single Nucleotide Variation)
rs12440459chr15:57402740 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
AHNAK0.857
ARHGAP310.85
LAMB20.817
RHOJ0.804
YAP10.802
PRKD30.799
EPS80.799
ITGB50.799
CD3020.797
PARD3B0.796

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PPEF1-0.517
GALNT14-0.505
ADTRP-0.497
ADRA1D-0.494
NRG1-0.487
ABCC12-0.478
IL12RB2-0.478
CYP26A1-0.474
RHO-0.471
PTPRR-0.47

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA"27188386
C0293704-toluidine4-toluidine results in increased expression of CGNL1 mRNA27638505
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of CGNL1 mRNA29067470
D000082AcetaminophenAcetaminophen affects the expression of CGNL1 mRNA17562736
D016604Aflatoxin B1Aflatoxin B1 affects the expression of CGNL1 protein20106945
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of CGNL1 mRNA21632981|2164198
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of CGNL1 gene27153756
D000535Aluminum[APP protein modified form binds to Aluminum] which results in increased expression of CGNL1 mRNA21298039
C006632arsenic trioxidearsenic trioxide results in decreased expression of CGNL1 mRNA26705709
D001280AtrazineAtrazine results in increased expression of CGNL1 mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of CGNL1 mRNA20106945|2163298
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of CGNL1 mRNA19770486
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of CGNL1 mRNA27195522
C006780bisphenol Abisphenol A results in decreased expression of CGNL1 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of CGNL1 gene28505145
D002251Carbon TetrachlorideCarbon Tetrachloride results in increased expression of CGNL1 mRNA17484886
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of CGNL1 mRNA20938992
C018021cobaltous chloridecobaltous chloride results in decreased expression of CGNL1 mRNA19320972
C018021cobaltous chloridecobaltous chloride results in decreased expression of CGNL1 mRNA24386269
D019327Copper SulfateCopper Sulfate results in decreased expression of CGNL1 mRNA19549813
D016572CyclosporineCyclosporine results in decreased expression of CGNL1 mRNA20106945|2556210
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of CGNL1 mRNA21266533
C000944dicrotophosdicrotophos results in increased expression of CGNL1 mRNA28302478
D002117CalcitriolCalcitriol results in decreased expression of CGNL1 mRNA16002434
C015835dimethyl-4-toluidinedimethyl-4-toluidine results in increased expression of CGNL1 mRNA27638505
D004237DiuronDiuron results in decreased expression of CGNL1 mRNA21551480
C118739entinostatentinostat results in increased expression of CGNL1 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA"27188386
C061365flusilazoleflusilazole results in increased expression of CGNL1 mRNA22382673
D005485FlutamideFlutamide results in decreased expression of CGNL1 mRNA24136188|2479361
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of CGNL1 mRNA20938992
D005839GentamicinsGentamicins results in decreased expression of CGNL1 mRNA22061828
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of CGNL1 mRNA20938992
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of CGNL1 mRNA23179753
C523799MRK 003CGNL1 results in increased susceptibility to MRK 00319903844
C051752nefazodonenefazodone results in decreased expression of CGNL1 mRNA24136188
D009532NickelNickel results in decreased expression of CGNL1 mRNA24768652|2558310
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of CGNL1 mRNA26272509
C086401pentabromodiphenyl etherpentabromodiphenyl ether results in decreased expression of CGNL1 mRNA26705709
C046012pentanalpentanal results in increased expression of CGNL1 mRNA26079696
C006253pirinixic acidpirinixic acid results in increased expression of CGNL1 mRNA18301758
C005556propionaldehydepropionaldehyde results in increased expression of CGNL1 mRNA26079696
C513428pyrachlostrobinpyrachlostrobin results in increased expression of CGNL1 mRNA27029645
D011794QuercetinQuercetin results in decreased expression of CGNL1 mRNA21632981
D012715Sesame OilSesame Oil results in increased expression of CGNL1 mRNA29191790
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of CGNL1 mRNA25895662
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of CGNL1 mRNA20106945|2163298
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of CGNL1 mRNA21570461
D019284ThapsigarginThapsigargin results in increased expression of CGNL1 protein24648495
D014050TolueneToluene results in increased expression of CGNL1 mRNA22967744
D014212TretinoinTretinoin results in decreased expression of CGNL1 mRNA23724009
D014212TretinoinTretinoin results in increased expression of CGNL1 mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of CGNL1 mRNA24935251|2627250
D014520UrethaneUrethane results in increased expression of CGNL1 mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CGNL1 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of CGNL1 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of CGNL1 mRNA29154799
D014635Valproic AcidValproic Acid results in increased expression of CGNL1 mRNA19101580|2317975
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of CGNL1 gene25560391
C025643vinclozolinvinclozolin results in increased expression of CGNL1 mRNA23034163
D024483Vitamin K 3Vitamin K 3 affects the expression of CGNL1 mRNA20044591
C088658zoledronic acidzoledronic acid results in decreased expression of CGNL1 mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003774motor activity-IEA-  
GO:0005515protein binding-IPI22891260  
GO ID GO Term Qualifier Evidence PubMed
GO:0007015actin filament organization-IMP22891260  
GO:0051058negative regulation of small GTPase mediated signal transduction-IMP22891260  
GO ID GO Term Qualifier Evidence PubMed
GO:0005923bicellular tight junction-IEA-  
GO:0016459myosin complex-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal